CatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical Development Program for Visugromab
CatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical...
Read MoreCatalYm’s Visugromab Phase 1/2a Data Demonstrating Clinical Proof-of-Concept for Reversing Resistance to Checkpoint Inhibitors through GDF-15 Neutralization Published in Nature
CatalYm’s Visugromab Phase 1/2a Data Demonstrating Clinical Proof-of-Concept for Reversing Resistance to...
Read MoreCatalYm Highlights Visugromab’s Potential to Treat Cachexia in Cancer Patients at International SCWD Conference
CatalYm Highlights Visugromab’s Potential to Treat Cachexia in Cancer Patients at International SCWD...
Read MoreCatalYm Announces Leadership Change
CatalYm Announces Leadership Change Munich, Germany, October 11, 2024 – CatalYm...
Read MoreCatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab
CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development...
Read MoreCatalYm Reports Impressive and Lasting Responses Including Multiple Complete Responses in Heavily Pretreated, Late- to Last-Line Metastatic NSCLC, Urothelial and Hepatocellular Cancer Patients Treated with Visugromab/Nivolumab Combination
CatalYm Reports Impressive and Lasting Responses Including Multiple Complete Responses in Heavily...
Read MoreCatalYm to Present Positive New Phase 2a Follow-up Data on GDF-15 Neutralizing Antibody Visugromab in Advanced NSCLC, Urothelial, and Hepatocellular Cancer at the 2024 ASCO Annual Meeting
CatalYm to Present Positive New Phase 2a Follow-up Data on GDF-15 Neutralizing...
Read MoreCatalYm Appoints Drug Development Leader Roy Baynes to its Board of Directors and Strengthens Scientific Advisory Board with Three Accomplished Lung and Bladder Cancer Specialists
CatalYm Appoints Drug Development Leader Roy Baynes to its Board of Directors...
Read MoreCatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023
CatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and...
Read MoreCatalYm Presents Data at SITC 2023 Annual Meeting Further Unraveling GDF-15-mediated Inhibition of T Cell Adhesion and a New Combination Approach for Visugromab with Bispecific T-Cell Engagers
CatalYm Presents Data at SITC 2023 Annual Meeting Further Unraveling GDF-15-mediated Inhibition...
Read More